Drugs / AF-130
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02652936 | Oct 2015 → Mar 2016 | — | Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AF-130 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02652936 ↗ |
| Route | Oral | “AF-130 oral capsules” NCT02652936 ↗ |